![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » KV PHARMACEUTICAL ANNOUNCES APPROVALS FOR GYNAZOLE-1
KV PHARMACEUTICAL ANNOUNCES APPROVALS FOR GYNAZOLE-1
August 17, 2005
KV Pharmaceutical has announced that it has received notification of approvals to market Gynazole-1 from one of its international licensees, Gedeon Richter.
Gedeon Richter is the third international licensee of KV Pharmaceutical to submit an application and receive approval for Gynazole-1, a one-dose prescription cream treatment for vaginal yeast infections from Candida. To date, Gedeon Richter has received approval to market Gynazole-1 in 15 of its 21 Eastern European countries and territories.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct